EC 1456

Drug Profile

EC 1456

Alternative Names: EC-1456; Folate-targeted tubulysin - Endocyte; Folate-tubulysin; Folic acid-tubulysin conjugate (EC1456) - Endocyte

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Endocyte
  • Class Antineoplastics; Biological toxins; Peptides
  • Mechanism of Action Folate receptor 1 antagonists; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Preclinical Breast cancer; Endometrial cancer

Most Recent Events

  • 24 Jan 2017 Phase-I clinical trials in Ovarian cancer (Late-stage disease) in USA (IV) (NCT03011320)
  • 03 Jan 2017 Endocyte plans an exploratory clinical trial for Ovarian cancer (Late-stage disease) in USA (NCT03011320)
  • 10 Oct 2016 Phase-I clinical trials in Non-small cell lung cancer (Second-line therapy or greater) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top